Skip to main content
Home > BioCentury on BioBusiness > Finance/Investment

Chronological Index of : Finance

 Current Issue
  • Ebb & Flow

    Money Raised in 2008 While many biotech companies are running short of cash and valuations are depressed by the confluence of crises …

    Published on 12/22/2008
  • Money Raised in 2008

    Ebb & Flow Money Raised in 2008 Last week, the biotech industry raised $109 million, bringing to $13.5 billion the total raised year-to-date. In 2007, a total of $30.4 billion was raised, including $2.9 billion in …

    Published on 12/22/2008
  • Ebb & Flow

    Money Raised in 2008 In good economic times, companies that run into problems can often avoid tough decisions - such as dropping programs or …

    Published on 12/15/2008
  • Money Raised in 2008

    Ebb & Flow Money Raised in 2008 Last week, the biotech industry raised $41 million, bringing to $13.3 billion the total raised year-to-date. In 2007, a total of $30.4 billion was raised, including $2.9 billion in …

    Published on 12/15/2008
  • Ebb & Flow

    Money Raised in 2008 With capital markets tight, biotech companies are looking for non-dilutive ways to guarantee access to new funds …

    Published on 12/8/2008
  • Money Raised in 2008

    Ebb & Flow Money Raised in 2008 For the last two weeks, the biotech industry raised $249 million, bringing to $13.3 billion the total raised year-to-date. In 2007, a total of $30.4 billion was raised, including $2.9…

    Published on 12/8/2008
  • Ebb & Flow

    NASDAQ Biotech changes Money Raised in 2008 A deal with Eli Lilly (NYSE:LLY) for exclusive U.S. rights to commercialize tadalafil for …

    Published on 11/24/2008
  • Money Raised in 2008

    Ebb & Flow Money Raised in 2008 Last week, the biotech industry raised $386 million, bringing to $13 billion the total raised year-to-date. In 2007, a total of $30.4 billion was raised, including $2.9 billion in …

    Published on 11/24/2008
  • NASDAQ Biotech changes

    Ebb & Flow NASDAQ Biotech changes All three of the companies due to be added to the NASDAQ Biotechnology Index were down last week. The Index itself lost 11%. The new names were announced Friday, Nov. 14, and the …

    Published on 11/24/2008
  • Ebb & Flow

    Money Raised in 2008 Two of the many micro-cap companies with a year or less of cash secured some breathing room last week. Cardiovascular and …

    Published on 11/17/2008
  • Money Raised in 2008

    Ebb & Flow Money Raised in 2008 Last week, the biotech industry raised $133 million, bringing to $12.7 billion the total raised year-to-date. In 2007, a total of $30.4 billion was raised, including $2.9 billion in …

    Published on 11/17/2008
  • Biotech exits

    Cover Story: Ebb & Flow Focus: The denominator effect Biotech exits SV Life Sciences Fund III (SVLSF III) closed in 2003 with total commitments of $393 million (plus $8 million of co-investments committed by …

    Published on 11/10/2008
  • The denominator effect

    The uncommitted Missing the targets Biotech exits Some of the largest public pension funds, crushed by losses in the public …

    Published on 11/10/2008
  • Ebb & Flow

    Money Raised in 2008 EPS watch In the largest biotech venture financing this year, cancer stem cell antibody company OncoMed received the $93 million …

    Published on 11/10/2008
  • EPS watch

    Ebb & Flow EPS watch At least five profitable biotech companies reported earnings last week. Despite beating the Street's EPS estimate of $0.75 by $0.01, Charles River (NYSE:CRL) lost a quarter of its market cap …

    Published on 11/10/2008
  • Missing the targets

    Cover Story: Ebb & Flow Focus: The denominator effect Missing the targets Since the end of June, the market value of funds held by the California Public Employees' Retirement System (CalPERS) has fallen 22% to $185.…

    Published on 11/10/2008
  • Money Raised in 2008

    Ebb & Flow Money Raised in 2008 Last week, the biotech industry raised $223 million, bringing to $12.6 billion the total raised year-to-date. In 2007, a total of $30.4 billion was raised, including $2.9 billion in …

    Published on 11/10/2008
  • The uncommitted

    Cover Story: Ebb & Flow Focus: The denominator effect The uncommitted As of Dec. 31, 2007, the California Public Employees' Retirement System (CalPERS) had committed to provide at least $2.1 billion in capital to at…

    Published on 11/10/2008
  • Earnings on deck

    Ebb & Flow Earnings on deck As earnings season winds down, at least three profitable biotechs will report earnings this week. Analysts expect Luminex (NASDAQ:LMNX) to swing to profitability on $25 million in …

    Published on 11/3/2008
  • Ebb & Flow

    Earnings on deck Rigel's round trip Money Raised in 2008 EPS watch Cardiovascular and pulmonary company Dyax (NASDAQ: DYAX) has found a bevy of ways…

    Published on 11/3/2008
  • Venture debt demands equity

    Venture debt Lenders are still offering venture debt and credit facilities despite the credit crunch. But their expectations include …

    Published on 11/3/2008
  • EPS watch

    Ebb & Flow EPS watch In a week that saw the S&P 500 gain more than 10%, at least 14 profitable biotechs and big pharmas reported earnings. Endo (NASDAQ:ENDP) added 22% in value after reporting 3Q08 EPS of $0.57, …

    Published on 11/3/2008
  • Money Raised in 2008

    Ebb & Flow Money Raised in 2008 Last week, the biotech industry raised $156 million, bringing to $12.4 billion the total raised year-to-date. In 2007, a total of $30.4 billion was raised, including $2.9 billion in …

    Published on 11/3/2008
  • Rigel's round trip

    Ebb & Flow Rigel's round trip Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) dropped 40% last week after presenting detailed data on its Phase II trial of rheumatoid arthritis compound R788. The data raised safety …

    Published on 11/3/2008
  • Venture debt

    Ebb & Flow Focus: Venture debt demands equity Venture debt In the first three quarters of 2008, private biotechs raised about $249 million via debt deals. Of the $249 million, $95 million was raised by EKR …

    Published on 11/3/2008

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993